<p>Abbreviations: OR = odds ratio; CI = confidence interval; BMI = body mass index; VTE = venous thromboembolism; PE = pulmonary embolism. A. a) Adjusted for all baseline characteristics shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100164#pone-0100164-t001" target="_blank">Table 1</a> as a fixed effect and for study site as a random effect. A selection of variables is displayed in the figures to improve legibility i.e. age, sex and all variables with statistical significant numbers. <b>B. Predictors for starting oral anticoagulation on the first treatment day (n = 750). C. Predictors for continuing parenteral anticoagulation until an international normalized ratio of ≥2 for 24 hours (n = 750).</b></p
<p>Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CI, confidence interval; CV...
BACKGROUND: Anticoagulation control is often summarized using the percentage of time spent in a ther...
Background: The efficacy and safety of vitamin K antagonists for the prevention of thromboembolism a...
Although patient self-management (PSM) of oral anticoagulation with vitamin K antagonists is recomme...
Although patient self-management (PSM) of oral anticoagulation with vitamin K antagonists is recomme...
International audience: In many countries, new oral anticoagulants are only covered for patients wit...
Contains fulltext : 220767.pdf (publisher's version ) (Open Access
The efficacy and safety of vitamin K antagonists (VKA) are related to the actual level of anticoagul...
Oral anticoagulant therapy is essential for the treat-ment and prevention of many thromboembolic dis...
<p>Model 1: Adjusted by age and initial NIHSS. Model 2: Adjusted by age, initial NIHSS, and thrombol...
Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The...
BACKGROUND: In patients receiving oral anticoagulation, improved control can reduce adverse outcomes...
<p>Only endpoints available in all studies are reported. NOAC = new oral anticoagulant drug; BID ...
textabstractVitamin K antagonists (VKAs) used for the prevention and treatment of thromboembolic dis...
BackgroundPatient adherence is an essential factor in obtaining an efficient oral anticoagulation us...
<p>Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CI, confidence interval; CV...
BACKGROUND: Anticoagulation control is often summarized using the percentage of time spent in a ther...
Background: The efficacy and safety of vitamin K antagonists for the prevention of thromboembolism a...
Although patient self-management (PSM) of oral anticoagulation with vitamin K antagonists is recomme...
Although patient self-management (PSM) of oral anticoagulation with vitamin K antagonists is recomme...
International audience: In many countries, new oral anticoagulants are only covered for patients wit...
Contains fulltext : 220767.pdf (publisher's version ) (Open Access
The efficacy and safety of vitamin K antagonists (VKA) are related to the actual level of anticoagul...
Oral anticoagulant therapy is essential for the treat-ment and prevention of many thromboembolic dis...
<p>Model 1: Adjusted by age and initial NIHSS. Model 2: Adjusted by age, initial NIHSS, and thrombol...
Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The...
BACKGROUND: In patients receiving oral anticoagulation, improved control can reduce adverse outcomes...
<p>Only endpoints available in all studies are reported. NOAC = new oral anticoagulant drug; BID ...
textabstractVitamin K antagonists (VKAs) used for the prevention and treatment of thromboembolic dis...
BackgroundPatient adherence is an essential factor in obtaining an efficient oral anticoagulation us...
<p>Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CI, confidence interval; CV...
BACKGROUND: Anticoagulation control is often summarized using the percentage of time spent in a ther...
Background: The efficacy and safety of vitamin K antagonists for the prevention of thromboembolism a...